Laminin-332 cleavage by matriptase alters motility parameters of prostate cancer cells

Prostate

Volumn 71, Issue 2, 2011, Pages 184-196

  Tripathi, Manisha ^a   Potdar, Alka A ^b   Yamashita, Hironobu ^a   Weidow, Brandy ^a   Cummings, Peter T ^b,c   Kirchhofer, Daniel ^d   Quaranta, Vito ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c OAK RIDGE NATIONAL LABORATORY   (United States)

^d GENENTECH INC   (United States)

Author keywords

cell migration; laminin 332; matriptase; prostate cancer; proteolysis; type II transmembrane serine protease

Indexed keywords

KALININ; MATRIPTASE; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; BETA CHAIN; CANCER GROWTH; CELL MIGRATION; CELL MOTILITY; CELL STRAIN LNCAP; CONTROLLED STUDY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; RAT; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; LAMININ; MALE; MICROSCOPY, PHASE-CONTRAST; PROSTATIC NEOPLASMS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; SERINE ENDOPEPTIDASES; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 78650977062     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21233     Document Type: Article

References (75)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-249.
2. Mundy GR,. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2 (8): 584-593.
3. Sherwood DR,. Cell invasion through basement membranes: An anchor of understanding. Trends Cell Biol 2006; 16 (5): 250-256.
4. Chambers AF, Groom AC, MacDonald IC,. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002; 2 (8): 563-572.
5. Kalluri R,. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3 (6): 422-433.
6. Lopez-Otin C, Matrisian LM,. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007; 7 (10): 800-808.
7. Woodward JK, Holen I, Coleman RE, Buttle DJ,. The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer. Bone 2007; 41 (6): 912-927.
8. Noel A, Gilles C, Bajou K, Devy L, Kebers F, Lewalle JM, Maquoi E, Munaut C, Remacle A, Foidart JM,. Emerging roles for proteinases in cancer. Invasion Metastasis 1997; 17 (5): 221-239.
9. Hintermann E, Quaranta V,. Epithelial cell motility on laminin-5: Regulation by matrix assembly, proteolysis, integrins and erbB receptors. Matrix Biol 2004; 23 (2): 75-85.
10. Aumailley M, Bruckner-Tuderman L, Carter WG, Deutzmann R, Edgar D, Ekblom P, Engel J, Engvall E, Hohenester E, Jones JC, Kleinman HK, Marinkovich MP, Martin GR, Mayer U, Meneguzzi G, Miner JH, Miyazaki K, Patarroyo M, Paulsson M, Quaranta V, Sanes JR, Sasaki T, Sekiguchi K, Sorokin LM, Talts JF, Tryggvason K, Uitto J, Virtanen I, von der Mark K, Wewer UM, Yamada Y, Yurchenco PD,. A simplified laminin nomenclature. Matrix Biol 2005; 24 (5): 326-332.
11. Ryan MC, Christiano AM, Engvall E, Wewer UM, Miner JH, Sanes JR, Burgeson RE,. The functions of laminins: Lessons from in vivo studies. Matrix Biol 1996; 15 (6): 369-381.
12. Guess CM, Quaranta V,. Defining the role of laminin-332 in carcinoma. Matrix Biol 2009; 28 (8): 445-455.
13. Marinkovich MP,. Tumour microenvironment: Laminin 332 in squamous-cell carcinoma. Nat Rev Cancer 2007; 7 (5): 370-380.
14. Hao J, Jackson L, Calaluce R, McDaniel K, Dalkin BL, Nagle RB,. Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer. Am J Pathol 2001; 158 (3): 1129-1135.
15. Nagle RB,. Role of the extracellular matrix in prostate carcinogenesis. J Cell Biochem 2004; 91 (1): 36-40.
16. Calaluce R, Beck SK, Bair EL, Pandey R, Greer KA, Hoying AM, Hoying JB, Mount DW, Nagle RB,. Human laminin-5 and laminin-10 mediated gene expression of prostate carcinoma cells. Prostate 2006; 66 (13): 1381-1390.
17. Davis TL, Cress AE, Dalkin BL, Nagle RB,. Unique expression pattern of the alpha6beta4 integrin and laminin-5 in human prostate carcinoma. Prostate 2001; 46 (3): 240-248.
18. Yamashita H, Shang M, Tripathi M, Jourquin J, Georgescu W, Liu S, Weidow B, Quaranta V,. Epitope mapping of function-blocking monoclonal antibody CM6 suggests a "weak" integrin binding site on the laminin-332 LG2 domain. J Cell Physiol 2010; 223 (3): 541-548.
19. Yamashita H, Tripathi M, Harris MP, Liu S, Weidow B, Zent R, Quaranta V,. The role of a recombinant fragment of laminin-332 in integrin alpha3beta1-dependent cell binding, spreading and migration. Biomaterials. 2010; 31 (19): 5110-5121.
20. Schenk S, Hintermann E, Bilban M, Koshikawa N, Hojilla C, Khokha R, Quaranta V,. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J Cell Biol 2003; 161 (1): 197-209.
21. Schenk S, Quaranta V,. Tales from the crypt[ic] sites of the extracellular matrix. Trends Cell Biol 2003; 13 (7): 366-375.
22. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V,. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. Science 1997; 277 (5323): 225-228.
23. Koshikawa N, Schenk S, Moeckel G, Sharabi A, Miyazaki K, Gardner H, Zent R, Quaranta V,. Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology. FASEB J 2004; 18 (2): 364-366.
24. Pirila E, Sharabi A, Salo T, Quaranta V, Tu H, Heljasvaara R, Koshikawa N, Sorsa T, Maisi P,. Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration. Biochem Biophys Res Commun 2003; 303 (4): 1012-1017.
25. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R, Shi GP,. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 2006; 281 (9): 6020-6029.
26. Veitch DP, Nokelainen P, McGowan KA, Nguyen TT, Nguyen NE, Stephenson R, Pappano WN, Keene DR, Spong SM, Greenspan DS, Findell PR, Marinkovich MP,. Mammalian tolloid metalloproteinase, and not matrix metalloprotease 2 or membrane type 1 metalloprotease, processes laminin-5 in keratinocytes and skin. J Biol Chem 2003; 278 (18): 15661-15668.
27. Amano S, Scott IC, Takahara K, Koch M, Champliaud MF, Gerecke DR, Keene DR, Hudson DL, Nishiyama T, Lee S, Greenspan DS, Burgeson RE,. Bone morphogenetic protein 1 is an extracellular processing enzyme of the laminin 5 gamma 2 chain. J Biol Chem 2000; 275 (30): 22728-22735.
28. Mydel P, Shipley JM, Adair-Kirk TL, Kelley DG, Broekelmann TJ, Mecham RP, Senior RM,. Neutrophil elastase cleaves laminin-332 (laminin-5) generating peptides that are chemotactic for neutrophils. J Biol Chem 2008; 283 (15): 9513-9522.
29. Udayakumar TS, Chen ML, Bair EL, Von Bredow DC, Cress AE, Nagle RB, Bowden GT,. Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration. Cancer Res 2003; 63 (9): 2292-2299.
30. Remy L, Trespeuch C, Bachy S, Scoazec JY, Rousselle P,. Matrilysin 1 influences colon carcinoma cell migration by cleavage of the laminin-5 beta3 chain. Cancer Res 2006; 66 (23): 11228-11237.
31. Nakashima Y, Kariya Y, Yasuda C, Miyazaki K,. Regulation of cell adhesion and type VII collagen binding by the beta3 chain short arm of laminin-5: Effect of its proteolytic cleavage. J Biochem 2005; 138 (5): 539-552.
32. Tripathi M, Nandana S, Yamashita H, Ganesan R, Kirchhofer D, Quaranta V,. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem 2008; 283 (45): 30576-30584.
33. Carter WG, Kaur P, Gil SG, Gahr PJ, Wayner EA,. Distinct functions for integrins alpha 3 beta 1 in focal adhesions and alpha 6 beta 4/bullous pemphigoid antigen in a new stable anchoring contact (SAC) of keratinocytes: Relation to hemidesmosomes. J Cell Biol 1990; 111 (6 Pt 2): 3141-3154.
34. Belkin AM, Stepp MA,. Integrins as receptors for laminins. Microsc Res Tech 2000; 51 (3): 280-301.
35. List K, Haudenschild CC, Szabo R, Chen W, Wahl SM, Swaim W, Engelholm LH, Behrendt N, Bugge TH,. Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis. Oncogene 2002; 21 (23): 3765-3779.
36. Saleem M, Adhami VM, Zhong W, Longley BJ, Lin CY, Dickson RB, Reagan-Shaw S, Jarrard DF, Mukhtar H,. A novel biomarker for staging human prostate adenocarcinoma: Overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1. Cancer Epidemiol Biomarkers Prev 2006; 15 (2): 217-227.
37. Warren M, Twohig M, Pier T, Eickhoff J, Lin CY, Jarrard D, Huang W,. Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: A tissue microarray and automated quantitative analysis. Appl Immunohistochem Mol Morphol 2009; 17 (1): 23-30.
38. Riddick AC, Shukla CJ, Pennington CJ, Bass R, Nuttall RK, Hogan A, Sethia KK, Ellis V, Collins AT, Maitland NJ, Ball RY, Edwards DR,. Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues. Br J Cancer 2005; 92 (12): 2171-2180.
39. Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K,. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 2005; 27 (4): 1061-1070.
40. Galkin AV, Mullen L, Fox WD, Brown J, Duncan D, Moreno O, Madison EL, Agus DB,. CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts. Prostate 2004; 61 (3): 228-235.
41. Sanders AJ, Parr C, Davies G, Martin TA, Lane J, Mason MD, Jiang WG,. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo. J Exp Ther Oncol 2006; 6 (1): 39-48.
42. Shia S, Stamos J, Kirchhofer D, Fan B, Wu J, Corpuz RT, Santell L, Lazarus RA, Eigenbrot C,. Conformational lability in serine protease active sites: Structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B. J Mol Biol 2005; 346 (5): 1335-1349.
43. Sanders AJ, Parr C, Mason MD, Jiang WG,. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med 2007; 20 (4): 613-619.
44. List K, Szabo R, Molinolo A, Sriuranpong V, Redeye V, Murdock T, Burke B, Nielsen BS, Gutkind JS, Bugge TH,. Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation. Genes Dev 2005; 19 (16): 1934-1950.
45. Bugge TH, List K, Szabo R,. Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front Biosci 2007; 12: 5060-5070.
46. Darragh MR, Bhatt AS, Craik CS,. MT-SP1 proteolysis and regulation of cell-microenvironment interactions. Front Biosci 2008; 13: 528-539.
47. List K,. Matriptase: A culprit in cancer? Future Oncol 2009; 5 (1): 97-104.
48. List K, Bugge TH, Szabo R,. Matriptase: Potent proteolysis on the cell surface. Mol Med 2006; 12 (1-3): 1-7.
49. Uhland K,. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006; 63 (24): 2968-2978.
50. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM,. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005; 24 (34): 5333-5343.
51. Netzel-Arnett S, Currie BM, Szabo R, Lin CY, Chen LM, Chai KX, Antalis TM, Bugge TH, List K,. Evidence for a matriptase-prostasin proteolytic cascade regulating terminal epidermal differentiation. J Biol Chem 2006; 281 (44): 32941-32945.
52. Bhatt AS, Welm A, Farady CJ, Vasquez M, Wilson K, Craik CS,. Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci USA 2007; 104 (14): 5771-5776.
53. Lee SL, Dickson RB, Lin CY,. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275 (47): 36720-36725.
54. Seitz I, Hess S, Schulz H, Eckl R, Busch G, Montens HP, Brandl R, Seidl S, Schomig A, Ott I,. Membrane-type serine protease-1/matriptase induces interleukin-6 and -8 in endothelial cells by activation of protease-activated receptor-2: Potential implications in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27 (4): 769-775.
55. Takeuchi T, Harris JL, Huang W, Yan KW, Coughlin SR, Craik CS,. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J Biol Chem 2000; 275 (34): 26333-26342.
56. Moran P, Li W, Fan B, Vij R, Eigenbrot C, Kirchhofer D,. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem 2006; 281 (41): 30439-30446.
57. Pankov R, Endo Y, Even-Ram S, Araki M, Clark K, Cukierman E, Matsumoto K, Yamada KM,. A Rac switch regulates random versus directionally persistent cell migration. J Cell Biol 2005; 170 (5): 793-802.
58. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100 (1): 57-70.
59. Bugge TH, Antalis TM, Wu Q,. Type II transmembrane serine proteases. J Biol Chem 2009; 284 (35): 23177-23181.
60. Szabo R, Bugge TH,. Type II transmembrane serine proteases in development and disease. Int J Biochem Cell Biol 2008; 40 (6-7): 1297-1316.
61. Cheng MF, Tzao C, Tsai WC, Lee WH, Chen A, Chiang H, Sheu LF, Jin JS,. Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: Correlation with clinicopathological parameters. Dis Esophagus 2006; 19 (6): 482-486.
62. Hoang CD, D'Cunha J, Kratzke MG, Casmey CE, Frizelle SP, Maddaus MA, Kratzke RA,. Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. Chest 2004; 125 (5): 1843-1852.
63. Tsai WC, Chao YC, Lee WH, Chen A, Sheu LF, Jin JS,. Increasing EMMPRIN and matriptase expression in hepatocellular carcinoma: Tissue microarray analysis of immunohistochemical scores with clinicopathological parameters. Histopathology 2006; 49 (4): 388-395. (Pubitemid 44401546)
64. Tsai WC, Chu CH, Yu CP, Sheu LF, Chen A, Chiang H, Jin JS,. Matriptase and survivin expression associated with tumor progression and malignant potential in breast cancer of Chinese women: Tissue microarray analysis of immunostaining scores with clinicopathological parameters. Dis Markers 2008; 24 (2): 89-99.
65. Lee JW, Yong Song S, Choi JJ, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY, Dickson RB, Bae DS,. Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol 2005; 36 (6): 626-633.
66. Tanimoto H, Shigemasa K, Tian X, Gu L, Beard JB, Sawasaki T, O'Brien TJ,. Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): Expression and prognostic value in ovarian cancer. Br J Cancer 2005; 92 (2): 278-283.
67. Santin AD, Cane S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Anfossi S, Roman JJ, O'Brien T, Pecorelli S,. The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer 2003; 98 (9): 1898-1904.
68. Kang JY, Dolled-Filhart M, Ocal IT, Singh B, Lin CY, Dickson RB, Rimm DL, Camp RL,. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res 2003; 63 (5): 1101-1105.
69. Oberst MD, Johnson MD, Dickson RB, Lin CY, Singh B, Stewart M, Williams A, al-Nafussi A, Smyth JF, Gabra H, Sellar GC,. Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters. Clin Cancer Res 2002; 8 (4): 1101-1107.
70. Rowe RG, Weiss SJ,. Breaching the basement membrane: Who, when and how? Trends Cell Biol 2008; 18 (11): 560-574.
71. Ozerlat I,. Cell migration: The benefit of being single. Nat Rev Mol Cell Biol 2009; 10 (12): 816.
72. Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E,. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 2009; 11 (11): 1287-1296.
73. Deisboeck TS, Demuth T, Mansury Y,. Correlating velocity patterns with spatial dynamics in glioma cell migration. Acta Biotheor 2005; 53 (3): 181-190.
74. Kumar N, Zaman MH, Kim HD, Lauffenburger DA,. A high-throughput migration assay reveals HER2-mediated cell migration arising from increased directional persistence. Biophys J 2006; 91 (4): L32-L34.
75. Ortiz-Urda S, Garcia J, Green CL, Chen L, Lin Q, Veitch DP, Sakai LY, Lee H, Marinkovich MP, Khavari PA,. Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science 2005; 307 (5716): 1773-1776.